Literature DB >> 9407340

Natural history of chronic hepatitis B virus infection: an immunopathological study.

C M Chu1, Y F Liaw.   

Abstract

Three clinicopathological phases of chronic hepatitis B virus (HBV) infection are identified. First, is immune tolerance of HBV. High levels of viraemia are associated with normal alanine aminotransferase (ALT) levels and minimal histological lesions. More than 30-40% of hepatocytes have the hepatitis B core antigen (HBcAg), predominantly in their nuclei. Maternally derived hepatitis B e antigen (HBeAg) crossing the placenta may result in the elimination of T helper cells responsive to HBeAg/HBcAg. This phase can last for periods ranging from a few weeks to 10 or more years until the immune tolerance is lost. Second, is the immune clearance of HBV. Intermediate levels of viraemia are associated with fluctuating ALT levels and active and ongoing hepatitis. Approximately 20-30% of hepatocytes have HBcAg, predominantly in their cytoplasm. Expression of pre-core defective HBV mutants during chronic HBV infection may lead to a reduction in the secretion of HBeAg and may trigger the beginning of the immuno-elimination phase. The mechanism of intrahepatic shift of HBcAg from the nucleus to the cytoplasm and the decreased levels of viraemia in this phase may be, at least in part, secondary to liver damage and regeneration. Third, is latent infection with residual integrated HBV. Undetectable viraemia is associated with normal ALT levels and no virus-induced liver damage. With regard to hepatocyte expression of HBsAg in chronic HBV infection, membrane staining of HBsAg on hepatocytes has been shown to correlate well with the presence of viraemia. The degree of cytoplasmic hepatitis B surface antigen (HBsAg) expression inversely correlates with the level of viraemia. Therefore, HBsAg carriers with high levels of viraemia have low levels of cytoplasmic hepatitis B surface antigen (HBsAg) expression, while those with low levels of viraemia have high levels of cytoplasmic HBsAg expression. However, several exceptions have been identified. High levels of viraemia associated with high levels of cytoplasmic HBsAg expression were recognized in patients with fibrosing cholestatic hepatitis. In contrast, low levels of viraemia associated with low levels of cytoplasmic HBsAg expression were recognized in patients with hepatitis C virus but not hepatitis D virus superinfection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407340     DOI: 10.1111/j.1440-1746.1997.tb00503.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  12 in total

1.  Prevalence of restriction fragment length polymorphism patterns of hepatitis B virus compatible with genotype D in Lebanon.

Authors:  A I Sharara; S Ramia; F Ramlawi; B Farhat; M Bahlawan; U Farhat; M Alameddine; E Nour; R Sayegh; C Yaghi; H Assi; A Ferzli; R Shatila
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-08       Impact factor: 3.267

2.  Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan.

Authors:  Chien-Hung Chen; Chuan-Mo Lee; Sheng-Nan Lu; Chi-Sin Changchien; Hock-Liew Eng; Chao-Min Huang; Jing-Houng Wang; Chao-Hung Hung; Tsung-Hui Hu
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

3.  Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance.

Authors:  Min-wei Li; Wei Hou; Jian-er Wo; Ke-zhou Liu
Journal:  J Zhejiang Univ Sci B       Date:  2005-07       Impact factor: 3.066

4.  Association of core promoter mutations of hepatitis B virus and viral load is different in HBeAg(+) and HBeAg(-) patients.

Authors:  Andi Utama; Marlinang Diarta Siburian; Sigit Purwantomo; Mariana Destila Bayu Intan; Tri Shinta Kurniasih; Rino Alvani Gani; Wenny Astuti Achwan; Syafruddin A R Lelosutan; Benyamin Lukito; Tantoro Harmono; Nasrul Zubir; Soewignjo Soemohardjo; Laurentius Adrianus Lesmana; Ali Sulaiman; Susan Tai
Journal:  World J Gastroenterol       Date:  2011-02-14       Impact factor: 5.742

Review 5.  HIV/HBV coinfection in children and antiviral therapy.

Authors:  Sara A Healy; Sonia Gupta; Ann J Melvin
Journal:  Expert Rev Anti Infect Ther       Date:  2013-03       Impact factor: 5.091

6.  siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection.

Authors:  Yong Chen; Ram I Mahato
Journal:  J Drug Target       Date:  2008-02       Impact factor: 5.121

7.  Levels of hepatitis B virus (HBV) replication during the nonreplicative phase: HBV quantification by real-time PCR in Korea.

Authors:  Hyung Joon Yim; Kwan Soo Byun; Yun Jung Chang; Yeon Seok Suh; Jong Eun Yeon; Chang Hong Lee; Jung Ah Kwon; Wangdon Yoo; Soo-Ok Kim; Sun Pyo Hong
Journal:  Dig Dis Sci       Date:  2007-04-11       Impact factor: 3.199

8.  The HBV DNA cutoff value for discriminating patients with HBeAgnegative chronic hepatitis B from inactive carriers.

Authors:  Eun Sun Kim; Yeon Seok Seo; Bora Keum; Ji Hoon Kim; Hyonggin A; Hyung Joon Yim; Yong Sik Kim; Yoon Tae Jeen; Hong Sik Lee; Hoon Jai Chun; Soon Ho Um; Chang Duck Kim; Ho Sang Ryu
Journal:  Hepat Mon       Date:  2011-05       Impact factor: 0.660

9.  Seroepidemiology of HBV infection in South Korea, 1995 through 1999.

Authors:  M K Jang; J Y Lee; J H Lee; Y B Kim; H Y Kim; M S Lee; C K Park; J Y Yoo
Journal:  Korean J Intern Med       Date:  2001-09       Impact factor: 2.884

10.  Testing for hepatitis B virus core antigen and e antigen may confer additional safety of donors' blood negative for heptitis B virus surface antigen.

Authors:  Fawwaz Shakir Al-Joudi; Maimunah Binti Mohd Arif; Zulaikha Binti Mohamed; Ismarulyusda Ishak; Suhair A Ahmed
Journal:  Asian J Transfus Sci       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.